Myeong J. Song

St. Vincent's Hospital
Suwon, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 79 publications

Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure.

Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure.

Journal: Targeted oncology

Published: April 18, 2026

Observational, Post-marketing Surveillance of Safety and Effectiveness of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C.

Observational, Post-marketing Surveillance of Safety and Effectiveness of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C.

Journal: Infectious diseases and therapy

Published: December 11, 2025

Hepatitis B core-related antigen as a multifaceted biomarker in chronic hepatitis B: implications for immune activity and hepatocellular carcinoma prediction.

Hepatitis B core-related antigen as a multifaceted biomarker in chronic hepatitis B: implications for immune activity and hepatocellular carcinoma prediction.

Journal: The Korean journal of internal medicine

Published: December 09, 2025

Prognostic Value of PALBI in Patients With Hepatocellular Carcinoma and Concurrent Chronic Kidney Disease: A Nomogram Development.

Prognostic Value of PALBI in Patients With Hepatocellular Carcinoma and Concurrent Chronic Kidney Disease: A Nomogram Development.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: November 20, 2025

Machine learning based hepatic safety score predicts decompensation in hepatocellular carcinoma systemic therapy.

Machine learning based hepatic safety score predicts decompensation in hepatocellular carcinoma systemic therapy.

Journal: NPJ digital medicine

Published: October 25, 2025

DNMT1 Facilitates the Progression of MASLD by Impeding Transcription Mediated by HNF4α and PPARα.

DNMT1 Facilitates the Progression of MASLD by Impeding Transcription Mediated by HNF4α and PPARα.

Journal: Clinical and molecular hepatology

Published: September 25, 2025

DNMT1 facilitates the progression of metabolic dysfunction-associated steatotic liver disease by impeding transcription mediated by HNF4α and PPARα.

DNMT1 facilitates the progression of metabolic dysfunction-associated steatotic liver disease by impeding transcription mediated by HNF4α and PPARα.

Journal: Clinical and molecular hepatology

Published: September 25, 2025

Challenges of an EMR-Based Hospital Alert Program for Micro-Elimination of Hepatitis C in Tertiary Referral Hospitals.

Challenges of an EMR-Based Hospital Alert Program for Micro-Elimination of Hepatitis C in Tertiary Referral Hospitals.

Journal: Journal of viral hepatitis

Published: September 09, 2025

Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab-bevacizumab.

Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab-bevacizumab.

Journal: Hepatology (Baltimore, Md.)

Published: March 04, 2025

Subset of Child-Pugh Score 7 Shows Comparable Survival Outcomes to Child-Pugh Score 6 in Patients with Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab.

Subset of Child-Pugh Score 7 Shows Comparable Survival Outcomes to Child-Pugh Score 6 in Patients with Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 10, 2025

Predicting Mortality and Cirrhosis-Related Complications with MELD3.0: A Multicenter Cohort Analysis.

Predicting Mortality and Cirrhosis-Related Complications with MELD3.0: A Multicenter Cohort Analysis.

Journal: Gut and liver

Published: December 10, 2024

Deletion of sphingosine 1-phosphate receptor 1 in myeloid cells reduces hepatic inflammatory macrophages and attenuates MASH.

Deletion of sphingosine 1-phosphate receptor 1 in myeloid cells reduces hepatic inflammatory macrophages and attenuates MASH.

Journal: Hepatology communications

Published: June 21, 2024

Showing 1-12 of 79

Last Updated: 09/26/2026